Share Price and Basic Stock Data
Last Updated: December 9, 2025, 4:48 pm
| PEG Ratio | 0.85 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kingfa Science & Technology (India) Ltd operates in the plastics sector, focusing on the manufacturing of various plastic products. The company has shown commendable growth, with revenue reported at ₹1,404 Cr for FY 2023, an increase from ₹1,048 Cr in FY 2022. This upward trajectory continued into FY 2024, with sales standing at ₹1,488 Cr. The quarterly sales data reveals a consistent performance, with Q4 FY 2024 sales reaching ₹404 Cr, slightly up from ₹394 Cr in Q3 FY 2024. This stability in revenue generation is encouraging, particularly in a sector facing challenges like fluctuating raw material prices and increasing competition. Overall, Kingfa’s ability to maintain sales growth reflects its resilience and effective market positioning. However, it is crucial to monitor how the company adapts to external pressures in the upcoming quarters.
Profitability and Efficiency Metrics
The profitability metrics for Kingfa Science & Technology indicate solid operational performance. The operating profit margin (OPM) for FY 2025 stood at 13%, a marked improvement from 9% in FY 2023. This improvement in margins is a positive sign, as it suggests that the company is managing its costs effectively while expanding its revenue base. The net profit for FY 2025 was reported at ₹153 Cr, up from ₹81 Cr in FY 2023, translating to an impressive net profit margin of 8.76%. The return on equity (ROE) is also noteworthy at 20.97%, showcasing efficient use of shareholders’ funds. However, the cash conversion cycle (CCC) of 80 days suggests potential inefficiencies in working capital management, which could impact liquidity if not addressed. Overall, while profitability appears robust, the company must streamline its cash flows to enhance financial flexibility.
Balance Sheet Strength and Financial Ratios
Examining Kingfa’s balance sheet reveals a strong financial foundation, characterized by minimal borrowings of just ₹19 Cr against total assets of ₹1,156 Cr. This low debt level translates into a comfortable debt-to-equity ratio of 0.05, indicating low financial risk. The interest coverage ratio (ICR) stands impressively at 35.23x, underscoring the company’s ability to meet interest obligations comfortably. Furthermore, the book value per share has risen significantly to ₹601.63 in FY 2025, reflecting a healthy accumulation of reserves, which now total ₹1,281 Cr. This strong reserve position can provide a buffer during economic downturns or when pursuing growth opportunities. However, the price-to-book value ratio of 4.92x could suggest that the stock is trading at a premium, warranting caution from prospective investors regarding valuation.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Kingfa Science & Technology exhibits a strong promoter commitment, with promoters holding 67.02% of the equity. This significant stake can instill confidence in retail investors, as a high promoter holding often aligns management interests with those of shareholders. Foreign institutional investors (FIIs) have increased their stake to 7.78%, while domestic institutional investors (DIIs) have also shown growing interest, now holding 8.75% of the company. This trend of increasing institutional participation suggests a positive perception of Kingfa’s growth potential. However, the public float has decreased to 16.45%, which could limit liquidity in the stock and may deter some investors. Thus, while the underlying confidence from institutional investors is a positive sign, the reduced public stake may introduce some volatility.
Outlook, Risks, and Final Insight
Looking ahead, Kingfa Science & Technology faces a mixed bag of opportunities and challenges. The growing demand for sustainable plastic solutions presents a significant growth avenue, particularly as industries shift towards eco-friendly materials. However, the company must navigate risks such as raw material price volatility and global supply chain disruptions, which could pressure margins. Additionally, competition from both domestic and international players remains fierce, necessitating continuous innovation and efficiency improvements. Investors should closely watch how the company manages its working capital, especially with a cash conversion cycle that remains relatively high. Ultimately, while Kingfa has demonstrated impressive growth and profitability, potential investors should weigh these strengths against the risks presented by market dynamics and operational efficiency.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Kingfa Science & Technology (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mitsu Chem Plast Ltd | 128 Cr. | 94.0 | 128/83.2 | 15.6 | 73.6 | 0.21 % | 10.4 % | 8.17 % | 10.0 |
| IIRM Holdings India Ltd | 487 Cr. | 71.4 | 131/69.4 | 26.5 | 21.3 | 0.00 % | 23.5 % | 18.6 % | 5.00 |
| Fiberweb (India) Ltd | 105 Cr. | 36.3 | 65.8/34.0 | 6.47 | 63.9 | 0.00 % | 10.0 % | 8.88 % | 10.0 |
| Deep Polymers Ltd | 98.0 Cr. | 40.5 | 74.2/35.7 | 19.8 | 37.5 | 0.00 % | 8.22 % | 6.10 % | 10.0 |
| DDev Plastiks Industries Ltd | 2,999 Cr. | 291 | 360/213 | 15.2 | 88.5 | 0.60 % | 33.9 % | 24.9 % | 1.00 |
| Industry Average | 1,530.08 Cr | 423.07 | 33.43 | 183.42 | 0.32% | 16.30% | 12.17% | 8.25 |
All Competitor Stocks of Kingfa Science & Technology (India) Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 346 | 351 | 340 | 366 | 339 | 351 | 394 | 404 | 416 | 418 | 440 | 470 | 462 |
| Expenses | 338 | 317 | 310 | 311 | 289 | 306 | 356 | 354 | 359 | 362 | 389 | 409 | 404 |
| Operating Profit | 8 | 34 | 31 | 55 | 50 | 45 | 38 | 51 | 57 | 56 | 51 | 60 | 58 |
| OPM % | 2% | 10% | 9% | 15% | 15% | 13% | 10% | 13% | 14% | 13% | 12% | 13% | 13% |
| Other Income | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 2 | 2 | 1 | 5 | 2 | 4 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 3 | 30 | 27 | 49 | 47 | 40 | 32 | 45 | 52 | 50 | 49 | 54 | 54 |
| Tax % | 27% | 26% | 25% | 26% | 25% | 25% | 25% | 26% | 25% | 26% | 30% | 23% | 26% |
| Net Profit | 2 | 22 | 20 | 37 | 35 | 30 | 24 | 34 | 39 | 37 | 35 | 42 | 40 |
| EPS in Rs | 2.04 | 18.24 | 16.70 | 30.24 | 28.93 | 24.44 | 20.09 | 27.70 | 32.26 | 30.77 | 28.60 | 34.60 | 32.86 |
Last Updated: August 1, 2025, 6:20 pm
Below is a detailed analysis of the quarterly data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 462.00 Cr.. The value appears to be declining and may need further review. It has decreased from 470.00 Cr. (Mar 2025) to 462.00 Cr., marking a decrease of 8.00 Cr..
- For Expenses, as of Jun 2025, the value is 404.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 409.00 Cr. (Mar 2025) to 404.00 Cr., marking a decrease of 5.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is 13.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 54.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 54.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 26.00%, marking an increase of 3.00%.
- For Net Profit, as of Jun 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 42.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 32.86. The value appears to be declining and may need further review. It has decreased from 34.60 (Mar 2025) to 32.86, marking a decrease of 1.74.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 178 | 219 | 314 | 427 | 602 | 702 | 742 | 627 | 1,048 | 1,404 | 1,488 | 1,745 | 1,790 |
| Expenses | 181 | 212 | 288 | 408 | 560 | 666 | 698 | 607 | 966 | 1,276 | 1,303 | 1,520 | 1,565 |
| Operating Profit | -3 | 6 | 27 | 19 | 41 | 35 | 43 | 20 | 82 | 128 | 185 | 225 | 226 |
| OPM % | -2% | 3% | 8% | 5% | 7% | 5% | 6% | 3% | 8% | 9% | 12% | 13% | 13% |
| Other Income | 0 | 0 | 1 | 4 | 6 | 4 | 3 | 6 | -22 | 2 | 3 | 9 | 11 |
| Interest | 7 | 8 | 7 | 2 | 2 | 2 | 4 | 3 | 5 | 7 | 6 | 7 | 6 |
| Depreciation | 3 | 3 | 3 | 3 | 6 | 8 | 9 | 11 | 13 | 14 | 18 | 22 | 23 |
| Profit before tax | -12 | -5 | 17 | 18 | 39 | 29 | 33 | 12 | 41 | 110 | 164 | 206 | 208 |
| Tax % | -31% | -35% | 38% | 30% | 36% | 35% | 26% | 55% | 26% | 26% | 25% | 26% | |
| Net Profit | -8 | -3 | 11 | 12 | 25 | 19 | 25 | 5 | 31 | 81 | 123 | 153 | 154 |
| EPS in Rs | -6.95 | -2.49 | 8.93 | 10.24 | 20.35 | 15.74 | 20.33 | 4.39 | 25.29 | 67.22 | 101.17 | 126.22 | 126.83 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 10% | -0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 62.50% | 466.67% | 9.09% | 108.33% | -24.00% | 31.58% | -80.00% | 520.00% | 161.29% | 51.85% | 24.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | 404.17% | -457.58% | 99.24% | -132.33% | 55.58% | -111.58% | 600.00% | -358.71% | -109.44% | -27.46% |
Kingfa Science & Technology (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 48% |
| 5 Years: | 44% |
| 3 Years: | 48% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 56% |
| 3 Years: | 51% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | 22% |
| Last Year: | 23% |
Last Updated: September 5, 2025, 9:05 am
Balance Sheet
Last Updated: December 4, 2025, 1:32 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 10 | 10 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 |
| Reserves | 5 | 2 | 109 | 234 | 293 | 312 | 336 | 342 | 372 | 454 | 576 | 716 | 1,281 |
| Borrowings | 62 | 75 | 16 | 42 | 21 | 17 | 46 | 71 | 46 | 42 | 33 | 43 | 19 |
| Other Liabilities | 31 | 41 | 95 | 119 | 159 | 210 | 202 | 246 | 449 | 502 | 373 | 384 | 421 |
| Total Liabilities | 105 | 125 | 230 | 405 | 485 | 551 | 596 | 671 | 880 | 1,010 | 994 | 1,156 | 1,735 |
| Fixed Assets | 24 | 25 | 29 | 76 | 88 | 85 | 107 | 129 | 126 | 123 | 252 | 244 | 290 |
| CWIP | 0 | 1 | 41 | 10 | 2 | 79 | 115 | 123 | 127 | 131 | 2 | 41 | 45 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 81 | 99 | 160 | 319 | 395 | 388 | 375 | 419 | 627 | 756 | 740 | 871 | 1,399 |
| Total Assets | 105 | 125 | 230 | 405 | 485 | 551 | 596 | 671 | 880 | 1,010 | 994 | 1,156 | 1,735 |
Below is a detailed analysis of the balance sheet data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,281.00 Cr.. The value appears strong and on an upward trend. It has increased from 716.00 Cr. (Mar 2025) to 1,281.00 Cr., marking an increase of 565.00 Cr..
- For Borrowings, as of Sep 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 43.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 24.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 421.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 384.00 Cr. (Mar 2025) to 421.00 Cr., marking an increase of 37.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,735.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,156.00 Cr. (Mar 2025) to 1,735.00 Cr., marking an increase of 579.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 290.00 Cr.. The value appears strong and on an upward trend. It has increased from 244.00 Cr. (Mar 2025) to 290.00 Cr., marking an increase of 46.00 Cr..
- For CWIP, as of Sep 2025, the value is 45.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Mar 2025) to 45.00 Cr., marking an increase of 4.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,399.00 Cr.. The value appears strong and on an upward trend. It has increased from 871.00 Cr. (Mar 2025) to 1,399.00 Cr., marking an increase of 528.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,735.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,156.00 Cr. (Mar 2025) to 1,735.00 Cr., marking an increase of 579.00 Cr..
Notably, the Reserves (1,281.00 Cr.) exceed the Borrowings (19.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -65.00 | -69.00 | 11.00 | -23.00 | 20.00 | 18.00 | -3.00 | -51.00 | 36.00 | 86.00 | 152.00 | 182.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 97 | 93 | 99 | 111 | 110 | 109 | 97 | 123 | 99 | 93 | 99 | 93 |
| Inventory Days | 54 | 64 | 85 | 69 | 85 | 63 | 67 | 100 | 110 | 94 | 76 | 82 |
| Days Payable | 66 | 72 | 127 | 108 | 108 | 119 | 115 | 152 | 181 | 155 | 110 | 94 |
| Cash Conversion Cycle | 85 | 85 | 57 | 72 | 86 | 53 | 49 | 71 | 28 | 32 | 66 | 80 |
| Working Capital Days | -7 | -14 | 66 | 59 | 96 | 59 | 55 | 57 | 39 | 45 | 78 | 85 |
| ROCE % | -9% | 4% | 22% | 9% | 13% | 9% | 10% | 4% | 16% | 25% | 30% | 31% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Flexicap Fund | 345,821 | 0.67 | 156.15 | N/A | N/A | N/A |
| SBI Conservative Hybrid Fund | 357,348 | 1.49 | 148.25 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| Diluted EPS (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| Cash EPS (Rs.) | 144.15 | 116.35 | 78.90 | 36.00 | 13.31 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 601.63 | 486.00 | 384.78 | 317.57 | 292.29 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 601.63 | 486.00 | 384.78 | 317.57 | 292.29 |
| Dividend / Share (Rs.) | 0.00 | 10.00 | 0.00 | 0.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 1440.64 | 1228.45 | 1159.08 | 865.13 | 517.93 |
| PBDIT / Share (Rs.) | 193.59 | 155.39 | 107.56 | 68.41 | 21.43 |
| PBIT / Share (Rs.) | 175.66 | 140.21 | 95.89 | 57.70 | 12.52 |
| PBT / Share (Rs.) | 170.16 | 135.58 | 90.49 | 34.14 | 9.79 |
| Net Profit / Share (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| PBDIT Margin (%) | 13.43 | 12.64 | 9.27 | 7.90 | 4.13 |
| PBIT Margin (%) | 12.19 | 11.41 | 8.27 | 6.66 | 2.41 |
| PBT Margin (%) | 11.81 | 11.03 | 7.80 | 3.94 | 1.88 |
| Net Profit Margin (%) | 8.76 | 8.23 | 5.79 | 2.92 | 0.84 |
| Return on Networth / Equity (%) | 20.97 | 20.81 | 17.47 | 7.96 | 1.50 |
| Return on Capital Employeed (%) | 29.00 | 28.66 | 24.65 | 17.08 | 3.92 |
| Return On Assets (%) | 13.22 | 12.32 | 8.05 | 3.49 | 0.79 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.04 | 0.06 |
| Total Debt / Equity (X) | 0.05 | 0.05 | 0.08 | 0.10 | 0.11 |
| Asset Turnover Ratio (%) | 1.62 | 1.48 | 1.49 | 1.35 | 0.98 |
| Current Ratio (X) | 2.02 | 1.80 | 1.37 | 1.30 | 1.45 |
| Quick Ratio (X) | 1.31 | 1.20 | 0.83 | 0.74 | 0.94 |
| Inventory Turnover Ratio (X) | 4.58 | 4.11 | 3.84 | 4.47 | 4.03 |
| Interest Coverage Ratio (X) | 35.23 | 33.55 | 19.95 | 15.67 | 7.84 |
| Interest Coverage Ratio (Post Tax) (X) | 23.97 | 22.84 | 13.47 | 11.19 | 2.61 |
| Enterprise Value (Cr.) | 3600.92 | 2398.91 | 1621.01 | 1546.18 | 724.65 |
| EV / Net Operating Revenue (X) | 2.06 | 1.61 | 1.15 | 1.48 | 1.16 |
| EV / EBITDA (X) | 15.36 | 12.75 | 12.44 | 18.66 | 27.92 |
| MarketCap / Net Operating Revenue (X) | 2.06 | 1.60 | 1.14 | 1.46 | 1.13 |
| Price / BV (X) | 4.92 | 4.03 | 3.45 | 3.99 | 2.00 |
| Price / Net Operating Revenue (X) | 2.06 | 1.60 | 1.14 | 1.46 | 1.13 |
| EarningsYield | 0.04 | 0.05 | 0.05 | 0.01 | 0.01 |
After reviewing the key financial ratios for Kingfa Science & Technology (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 144.15. This value is within the healthy range. It has increased from 116.35 (Mar 24) to 144.15, marking an increase of 27.80.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 601.63. It has increased from 486.00 (Mar 24) to 601.63, marking an increase of 115.63.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 601.63. It has increased from 486.00 (Mar 24) to 601.63, marking an increase of 115.63.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 10.00 (Mar 24) to 0.00, marking a decrease of 10.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,440.64. It has increased from 1,228.45 (Mar 24) to 1,440.64, marking an increase of 212.19.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 193.59. This value is within the healthy range. It has increased from 155.39 (Mar 24) to 193.59, marking an increase of 38.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 175.66. This value is within the healthy range. It has increased from 140.21 (Mar 24) to 175.66, marking an increase of 35.45.
- For PBT / Share (Rs.), as of Mar 25, the value is 170.16. This value is within the healthy range. It has increased from 135.58 (Mar 24) to 170.16, marking an increase of 34.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For PBDIT Margin (%), as of Mar 25, the value is 13.43. This value is within the healthy range. It has increased from 12.64 (Mar 24) to 13.43, marking an increase of 0.79.
- For PBIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.41 (Mar 24) to 12.19, marking an increase of 0.78.
- For PBT Margin (%), as of Mar 25, the value is 11.81. This value is within the healthy range. It has increased from 11.03 (Mar 24) to 11.81, marking an increase of 0.78.
- For Net Profit Margin (%), as of Mar 25, the value is 8.76. This value is within the healthy range. It has increased from 8.23 (Mar 24) to 8.76, marking an increase of 0.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 20.97. This value is within the healthy range. It has increased from 20.81 (Mar 24) to 20.97, marking an increase of 0.16.
- For Return on Capital Employeed (%), as of Mar 25, the value is 29.00. This value is within the healthy range. It has increased from 28.66 (Mar 24) to 29.00, marking an increase of 0.34.
- For Return On Assets (%), as of Mar 25, the value is 13.22. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 13.22, marking an increase of 0.90.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.05. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.62. It has increased from 1.48 (Mar 24) to 1.62, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.02. This value is within the healthy range. It has increased from 1.80 (Mar 24) to 2.02, marking an increase of 0.22.
- For Quick Ratio (X), as of Mar 25, the value is 1.31. This value is within the healthy range. It has increased from 1.20 (Mar 24) to 1.31, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.58. This value is within the healthy range. It has increased from 4.11 (Mar 24) to 4.58, marking an increase of 0.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.23. This value is within the healthy range. It has increased from 33.55 (Mar 24) to 35.23, marking an increase of 1.68.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.97. This value is within the healthy range. It has increased from 22.84 (Mar 24) to 23.97, marking an increase of 1.13.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,600.92. It has increased from 2,398.91 (Mar 24) to 3,600.92, marking an increase of 1,202.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 2.06, marking an increase of 0.45.
- For EV / EBITDA (X), as of Mar 25, the value is 15.36. This value exceeds the healthy maximum of 15. It has increased from 12.75 (Mar 24) to 15.36, marking an increase of 2.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.06, marking an increase of 0.46.
- For Price / BV (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has increased from 4.03 (Mar 24) to 4.92, marking an increase of 0.89.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.06, marking an increase of 0.46.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kingfa Science & Technology (India) Ltd:
- Net Profit Margin: 8.76%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 29% (Industry Average ROCE: 16.3%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 20.97% (Industry Average ROE: 12.17%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 32.5 (Industry average Stock P/E: 33.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.05
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.76%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Plastics - Plastic & Plastic Products | Dhun Building, 3rd Floor, Chennai (Madras) Tamil Nadu 600002 | cs@kingfaindia.com http://www.kingfaindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bo Jingen | Managing Director |
| Mr. Doraiswami Balaji | Executive Director |
| Mr. Sun Yajie | Executive Director |
| Ms. Nilima Ramrao Shinde | Ind. Non-Executive Director |
| Mr. S K Subramanyan | Ind. Non-Executive Director |
| Mr. Ramachandran Sudhinder | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Kingfa Science & Technology (India) Ltd?
Kingfa Science & Technology (India) Ltd's intrinsic value (as of 09 December 2025) is 5875.77 which is 55.61% higher the current market price of 3,776.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 5,111 Cr. market cap, FY2025-2026 high/low of 4,987/2,451, reserves of ₹1,281 Cr, and liabilities of 1,735 Cr.
What is the Market Cap of Kingfa Science & Technology (India) Ltd?
The Market Cap of Kingfa Science & Technology (India) Ltd is 5,111 Cr..
What is the current Stock Price of Kingfa Science & Technology (India) Ltd as on 09 December 2025?
The current stock price of Kingfa Science & Technology (India) Ltd as on 09 December 2025 is 3,776.
What is the High / Low of Kingfa Science & Technology (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kingfa Science & Technology (India) Ltd stocks is 4,987/2,451.
What is the Stock P/E of Kingfa Science & Technology (India) Ltd?
The Stock P/E of Kingfa Science & Technology (India) Ltd is 32.5.
What is the Book Value of Kingfa Science & Technology (India) Ltd?
The Book Value of Kingfa Science & Technology (India) Ltd is 955.
What is the Dividend Yield of Kingfa Science & Technology (India) Ltd?
The Dividend Yield of Kingfa Science & Technology (India) Ltd is 0.00 %.
What is the ROCE of Kingfa Science & Technology (India) Ltd?
The ROCE of Kingfa Science & Technology (India) Ltd is 30.6 %.
What is the ROE of Kingfa Science & Technology (India) Ltd?
The ROE of Kingfa Science & Technology (India) Ltd is 23.2 %.
What is the Face Value of Kingfa Science & Technology (India) Ltd?
The Face Value of Kingfa Science & Technology (India) Ltd is 10.0.